XORTX Therapeutics Inc <XRTX.V> expected to post a loss of 33 cents a share - Earnings Preview

• XORTX Therapeutics Inc XRTX.V is expected to report results on March 31 (estimated) for the period ending December 31 2024

• ​LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of 33 cents per share.

• The one available analyst rating on the shares is "buy".

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for XORTX Therapeutics Inc is $14.00​, above​ its last closing price of $0.96. ​​​

This summary was machine generated March 28 at 20:38 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)